From: CSP
By Angel Abcede, Senior Editor/Tobacco, CSP
WASHINGTON – One of the byproducts of the U.S. Food and Drug Administration’s (FDA’s) round of public discussion around nicotine levels in cigarettes is a rush of reports surrounding one of the tobacco category’s biggest challenges: the black market.
Illicit trade is a big argument that major tobacco makers put up against any potential standard for lowering nicotine levels in cigarettes sold in the United States.
